Oropharyngeal Cancer (CUE-101 Neoadjuvant)

Oropharyngeal Cancer (CUE-101 Neoadjuvant)

Washington University School of Medicine is currently conducting a Phase 2 non-randomized multi-arm study evaluating the safety and tolerability of our lead candidate, CUE-101, administered as a neoadjuvant therapy (prior to surgery or chemo-radiation therapy) in treatment naïve, HLA-A*0201 positive patients with newly diagnosed, locally advanced, human papilloma virus (HPV16+) oropharyngeal squamous-cell carcinoma (OPSCC).

For more information visit clinicaltrials.gov.

About Oropharyngeal Squamous-Cell Carcinoma

Human papilloma virus (HPV) can infect the oropharynx (back of the throat, including the base of the tongue and tonsils), causing oropharyngeal cancer. HPV is thought to cause 70% of oropharyngeal cancers in the United States with almost 11,000 estimated deaths in 2021. Oropharyngeal cancer incidence is increasing and men are more than twice as likely to develop it as women.1-3


  1. American Cancer Society: Cancer Facts and Figures 2021. American Cancer Society, 2021. Available online Exit Disclaimer. Last accessed October 8, 2021.
  2. Parkin DM, Bray F, Ferlay J, et al.: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2): 153-6, 2001. PUBMED Abstract
  3. Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Lippincott Williams & Wilkins, 2011, pp 729-80.